A Phase 1 Study of BMS-986453 CAR T Cell Therapy in People With Multiple Myeloma

Full Title

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma

Purpose

Researchers want to find the best dose of BMS-986453 to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.

BMS-986453 is a form of chimeric antigen receptor (CAR) T cell therapy, a type of cellular immunotherapy. With CAR T cell therapy, white blood cells called T cells are removed from your body. The T cells are altered in a lab to recognize proteins on your cancer cells. They are then multiplied to larger numbers and returned to your body to find and destroy cancer cells.

BMS-986453 targets proteins called BCMA and GPRC5D on myeloma cells. It is given intravenously (by vein).

Contact

For more information and to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-2091.